Results 21 to 30 of about 1,988,593 (307)

A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]

, 2015
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core   +1 more source

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Haematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza   +27 more
doaj   +1 more source

Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation [PDF]

, 2012
The mitochondrial respiratory chain (MRC) consists of protein complexes I, II, III, IV and V that support oxidative phosphorylation (OXPHOS), which depends on electron transport to generate adenosine triphosphate (ATP).
Flis, Krzysztof, Skorski, Tomasz, Bhatia, Ravi, Irvine, David, Bhatia, R., Copland, Mhairi, Irvine, D., Copland, M., Skorski, T., Flis, K.   +9 more
core   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +2 more sources

Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor

Haematologica, 2008
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara, Rossana Maffei, Silvia Martinelli, Annalisa Arcari, Federico Piacentini, Elena Trabacchi, Pierluigi Alfieri, Angela Ferrari, Giovanna Leonardi, Gabriele Luppi, Giuseppe Longo, Daniele Vallisa, Roberto Marasca, Giuseppe Torelli   +13 more
doaj   +1 more source

Report of an Unusual Case: Testicular Involvement of Chronic Myeloid Leukemia 10 Years after the Complete Response [PDF]

Journal of Clinical and Diagnostic Research, 2014
Testicular extra-medullary myeloid cell tumours are rare tumours presenting in most cases with painless testicular swelling. We present here a case of 21-year-old man with painless scrotal swelling.
Cem Nedim Yuceturk, Berat Cem Ozgur, Hasmet Sarici, Pelin Borcek, Onur Telli   +4 more
doaj   +1 more source

Bosutinib for Chronic Myeloid Leukemia [PDF]

Rare Cancers and Therapy, 2015
In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option.
Breccia, Massimo, Binotto, Gianni
openaire   +2 more sources

Comparative analysis of blood lymphocytes of patients with acute and chronic myeloid leukemia by surface and intracellular α1-acid glycoprotein and fibronectin

Біологічні студії, 2014
The exposition of α1-acid glycoprotein and fibronectin on the surface and inside the lymphocytes of healthy donors and hematological patients with acute and chronic myeloid leukemia were studied.
G. S. Маslak
doaj   +1 more source

A Case of Chronic Myeloid Leukemia Presenting with Osteoid Osteoma: A Diagnostic Dilemma

Asian Pacific Journal of Cancer Care, 2021
Chronic myeloid leukemia is a hematological malignancy resulting from a clonal proliferation of hematopoietic stem cells of the myeloid series. It is developed by chromosomal translocation.
Mannavi Suman, Anis Bandyopadhyay, Arnab Kumar Ghosh, Sk Rahamatulla, Alakananda Choudhury   +4 more
doaj   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source